Pfizer Inc.

Stock Exchange: XNYS • Ticker: PFE • HQ: New York, NY, US • Employees: 97,900

Ranking by technical area
Ranking by strategic pillar

Performance

Pfizer rises two places to 14th, having improved in specific areas. It moved a high proportion of projects along its pipeline, and provides stronger evidence that it implements its equitable pricing strategies and monitors prices and mark ups. It has two long-standing donation programmes with wide reach. It is relatively strong in strengthening supply chains, and has several innovative initiatives related to health financing. However, in access management, it does not have performance incentives linked to its access-related targets, and the transparency of its stakeholder engagement activities is limited. It performs poorly in all areas of Market Influence & Compliance, and was found in breach of corruption laws in a country in scope. Its patenting strategy lacks transparency.

Change since 2014

Has a new strategy for its Global Established Products Business Unit, which evaluates assets and capabilities to address leading causes of high-burden diseases in low-and middle-income countries.

Has been found in breach of laws and codes of conduct multiple times since 2014.

Moved a substantial portion of its R&D projects along the pipeline.

Signed the Declaration by the Pharmaceutical, Biotechnology and Diagnostics Industries on Combating Antimicrobial Resistance in January 2016.

Has implemented equitable pricing for Sayana Press®, targeting 69 countries with a price of USD 1 per dose.

Has improved its accountability for its sales agents’ pricing practices.

Has implemented a drug recall policy.

Has still not set targets for registering products for high-burden diseases.

Provides price and volume-of-sales information.

Still has not published a policy on where and when it will file for or enforce patent rights.

Has made employees available to the USAID/Indonesia Expanding Maternal and Neonatal Survival project in partnership with NGO RTI International.

Opportunities

Expand its access strategy to cover more relevant products. Pfizer can expand its access strategies to cover more products for diseases in scope, for example, by piloting a variety of healthcare interventions. Pfizer can expand equitable pricing to more products for high-burden diseases, and implement intra-country equitable pricing in markets with high inequality and high out-of-pocket spending on healthcare.

Publish a position on where it will file for or enforce patents. Pfizer can develop and disclose a public position on how it plans to file for and enforce its patents. This would give drug procurement agencies and generic medicine manufacturers greater confidence to act. In tandem, Pfizer can publish the status of its patents, to clearly show where products are on and off patent, and when they are due to expire.

Set access provisions for pipeline projects. Pfizer can make plans for the accessibility of future products early in the product development process, particularly for unique products that fill key product gaps in low- and middle-income countries (e.g., for its pre-clinical Group B streptococcus vaccine candidate).

Expand anonymity provisions for misconduct reporting. Pfizer can expand its anonymity guarantee for whistle-blowers to clarify guidance to employees in all countries. This would increase the chance of misconduct being reported and tackled.

Ensure access to relevant products gained through Hospira acquisition. Pfizer can implement access strategies for new and existing products gained through its acquisition of Hospira, particularly for products that are important in hospital and emergency situations.

Ensure access to products on the WHO EML. Pfizer has one of the largest numbers of products on the WHO Model Essential Medicines List (EML). It can evaluate access barriers to these products in all low- and middle-income countries. It can ensure their availability and affordability, aligning with demand and the availability of alternative products in specific countries.

Sales and operations

Pfizer operates through four segments: Global Innovative Pharmaceutical; Global Vaccines, Oncology and Consumer Healthcare; and Global Established Pharmaceutical. The company’s core therapeutic areas are: cardiovascular and metabolic disease, immunology, inflammation, neuroscience, oncology, vaccines, and pain and sensory. Pfizer holds a 12.6% stake in ViiV Healthcare, a joint venture with GSK and Shionogi focused solely on HIV/AIDS medicines. In September 2015, the company completed the acquisition of Hospira, a provider of injectable medicines, infusion technologies and biosimilars for approximately USD 17 bn. The company has sales in 86 countries within the scope of the Index.

Sales in countries in scope
Sales by division
Sales by region

Portfolio and pipeline

Pfizer has a large portfolio of 98 relevant products and a small pipeline of 10 R&D projects that address the needs of people in countries in scope.

Its products consist of medicines and vaccines, and cover a wide range of high-burden diseases: including respiratory diseases, meningitis, diabetes, epilepsy, HIV/AIDS and hypertensive and ischaemic heart disease.

The company has medicines and vaccines in development that target four communicable diseases, three non-communicable diseases (NCDs) and two maternal and neonatal health conditions.

Compared to other companies, Pfizer has moved a large proportion of the products in its pipeline from one stage of development to another. This includes gaining approval for Trumenba®, its meningococcal group B vaccine in October 2014. A low proportion of Pfizer’s R&D projects target high-priority product gaps with low commercial incentive.

Portfolio and pipeline

Pfizer has a large portfolio of 98 relevant products and a small pipeline of 10 R&D projects that address the needs of people in countries in scope.

Its products consist of medicines and vaccines, and cover a wide range of high-burden diseases: including respiratory diseases, meningitis, diabetes, epilepsy, HIV/AIDS and hypertensive and ischaemic heart disease.

The company has medicines and vaccines in development that target four communicable diseases, three non-communicable diseases (NCDs) and two maternal and neonatal health conditions.

Compared to other companies, Pfizer has moved a large proportion of the products in its pipeline from one stage of development to another. This includes gaining approval for Trumenba®, its meningococcal group B vaccine in October 2014. A low proportion of Pfizer’s R&D projects target high-priority product gaps with low commercial incentive.

Pfizer’s portfolio targets all disease categories and covers 32 diseases in scope.

Pipeline projects

Pfizer is working via ViiV Healthcare on an HIV/AIDS integrase inhibitor, which is currently in phase II of clinical development.

First-line treatments and essential medicines

62% of Pfizer’s medicines and vaccines are on the WHO EML and/or are first-line treatments: e.g., its pneumococcal 13-valent vaccine (Prevnar 13®), ACWY meningococcal vaccine (Mencevax®) and atorvastatin (Lipitor®).

Pipeline by stage of development
– Innovative medicines and vaccines

Pfizer’s innovative pipeline includes medicines for HIV/AIDS, type 2 diabetes, schizophrenia and ischaemic heart disease, as well as vaccines for Clostridium difficile, MRSA and group B streptococcus.

Pipeline by stage of development
– Adaptive medicines and vaccines

Pfizer gained approval for self-injection of its contraceptive Sayana Press® and a multi-dose preparation of Prevnar 13®, a conjugate pneumococcal vaccine. Both aim to improve access in relevant countries.

Please refer to the pdf of the report card (that can be downloaded here) for information on Pfizer’s performance per technical area.

Sign up to receive updates about our work.